文献速递甲状腺疾病

名称有何影响?伴乳头状核特征的非浸润性甲状腺滤泡性肿瘤命名修订的成本效益分析

What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision.
PubMed 文献 · Thyroid · 2022-01-07

该成本效益分析用马尔可夫模型模拟NIFTP按非恶性肿瘤降级管理(腺叶切除加减少随访)与按包裹性滤泡型乳头状甲状腺癌管理(部分患者行补全甲状腺切除或放射性碘消融并癌症随访)两种策略。5年模拟中降级管理每例总成本12380.99美元、获得5.00质量调整生命年,按癌管理每例总成本16264.03美元、获得4.97质量调整生命年,每例节省3883.05美元、增加0.03质量调整生命年,敏感性分析结果持续。

要点

  • 5年模拟中NIFTP降级管理每例成本12380.99美元,按癌管理为16264.03美元。
  • 降级管理获得5.00质量调整生命年,按癌管理获得4.97质量调整生命年。
  • 每例节省3883.05美元并增加0.03质量调整生命年,敏感性分析结果持续。

核心结论

  • 与传统管理相比,NIFTP降级管理每例估计节省3883.05美元并增加0.03质量调整生命年。
  • 作者表明这些发现在敏感性分析中持续存在,已考虑复发率、监测方法和其他模型输入的变异性。

研究设计与样本

  • 成本效益分析,通过构建马尔可夫模型模拟NIFTP的两种管理策略,并模拟诊断后5年和20年。
  • 策略一为按NIFTP降级管理,即腺叶切除加减少随访;策略二为按包裹性滤泡型乳头状甲状腺癌管理,即部分患者行补全甲状腺切除或放射性碘消融并按癌随访。
  • 测量总成本和生命质量年,并对所有变量进行单因素敏感性分析。

主要发现

  • 5年模拟期内,NIFTP降级管理每例总成本为12380.99美元,按eFVPTC管理每例总成本为16264.03美元,5年内节省3883.05美元。
  • NIFTP管理获得5.00质量调整生命年,按eFVPTC管理获得4.97质量调整生命年。
  • 敏感性分析显示,在单个变量的敏感性范围内,NIFTP管理始终成本更低且质量调整生命年更高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The noninvasive subtype of encapsulated follicular variant of papillary thyroid carcinoma (eFVPTC) has been reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in 2016 to reflect the indolent behavior and favorable prognosis of this type of tumor. This terminology change has also de-escalated its management approach from cancer treatment to a more conservative treatment strategy befitting a benign thyroid neoplasm. Objective: To characterize the reduced health care costs and improved quality of life (QOL) from management of NIFTP as a nonmalignant tumor compared with the previous management as eFVPTC. Methods: A cost-effectiveness analysis was performed by creating Markov models to simulate two management strategies for NIFTP: (i) de-escalated management of the tumor as NIFTP involving lobectomy with reduced follow-up, (ii) management of the tumor as eFVPTC involving completion thyroidectomy/radioactive iodine ablation for some patients, and follow-up recommended for carcinoma. The model was simulated for 5 and 20 years following diagnosis of NIFTP. Aggregate costs and quality-life years were measured. One-way sensitivity analysis was performed for all variables. Results: Over a five-year simulation period, de-escalated management of NIFTP had a total cost of $12,380.99 per patient while the more aggressive management of the tumor as eFVPTC had a total cost of $16,264.03 per patient (saving $3883.05 over five years). Management of NIFTP provided 5.00 quality-adjusted life years, whereas management as eFVPTC provided 4.97 quality-adjusted life years. Sensitivity analyses showed that management of NIFTP always resulted in lower costs and greater quality-adjusted life years (QALYs) over the sensitivity ranges for individual variables. De-escalated management for NIFTP is expected to produce ∼$6-42 million in cost savings over a five-year period for these patients, and incremental 54-370 QALYs of increased utility in the United States. Conclusion: The degree of cost savings and improved patient utility of de-escalated NIFTP management compared with traditional management was estimated to be $3883.05 and 0.03 QALYs per patient. We demonstrate that these findings persisted in sensitivity analysis to account for variability in recurrence rate, surveillance approaches, and other model inputs. These findings allow for greater understanding of the economic and QOL impact of the NIFTP reclassification.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Mehta V, Naraparaju A, Liao D, et al. What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision. Thyroid. 2022. PMID: 34915744. doi:10.1089/thy.2021.0486

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。